277 related articles for article (PubMed ID: 26392505)
21. Is in vitro antibiotic combination more effective than single-drug therapy against anthrax?
Athamna A; Athamna M; Nura A; Shlyakov E; Bast DJ; Farrell D; Rubinstein E
Antimicrob Agents Chemother; 2005 Apr; 49(4):1323-5. PubMed ID: 15793105
[TBL] [Abstract][Full Text] [Related]
22. In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis.
Athamna A; Athamna M; Medlej B; Bast DJ; Rubinstein E
J Antimicrob Chemother; 2004 Apr; 53(4):609-15. PubMed ID: 14998982
[TBL] [Abstract][Full Text] [Related]
23. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.
Vietri NJ; Purcell BK; Tobery SA; Rasmussen SL; Leffel EK; Twenhafel NA; Ivins BE; Kellogg MD; Webster WM; Wright ME; Friedlander AM
J Infect Dis; 2009 Feb; 199(3):336-41. PubMed ID: 19099484
[TBL] [Abstract][Full Text] [Related]
24. Bioterrorism. Researchers question obsession with Cipro.
Enserink M
Science; 2001 Oct; 294(5543):759-61. PubMed ID: 11679638
[No Abstract] [Full Text] [Related]
25. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques.
Grossman TH; Anderson MS; Drabek L; Gooldy M; Heine HS; Henning LN; Lin W; Newman JV; Nevarez R; Siefkas-Patterson K; Radcliff AK; Sutcliffe JA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784679
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Esel D; Doganay M; Sumerkan B
Int J Antimicrob Agents; 2003 Jul; 22(1):70-2. PubMed ID: 12842331
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.
Kao LM; Bush K; Barnewall R; Estep J; Thalacker FW; Olson PH; Drusano GL; Minton N; Chien S; Hemeryck A; Kelley MF
Antimicrob Agents Chemother; 2006 Nov; 50(11):3535-42. PubMed ID: 17065619
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial susceptibility of Bacillus anthracis strains from Hungary.
Kreizinger Z; Sulyok KM; Makrai L; Rónai Z; Fodor L; Jánosi S; Gyuranecz M
Acta Vet Hung; 2016 Jun; 64(2):141-7. PubMed ID: 27342086
[TBL] [Abstract][Full Text] [Related]
29. Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections, with focus on doxycycline.
Hamad T; Hellmark B; Nilsdotter-Augustinsson Å; Söderquist B
APMIS; 2015 Dec; 123(12):1055-60. PubMed ID: 26547372
[TBL] [Abstract][Full Text] [Related]
30. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.
Martin SW; Tierney BC; Aranas A; Rosenstein NE; Franzke LH; Apicella L; Marano N; McNeil MM
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):393-401. PubMed ID: 15717323
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
Heine HS; Bassett J; Miller L; Purcell BK; Byrne WR
Antimicrob Agents Chemother; 2010 Oct; 54(10):4471-3. PubMed ID: 20643899
[TBL] [Abstract][Full Text] [Related]
32. In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics.
Giacometti A; Cirioni O; Barchiesi F; Scalise G
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):115-8. PubMed ID: 11035243
[TBL] [Abstract][Full Text] [Related]
33. Raxibacumab for the treatment of inhalational anthrax.
Migone TS; Subramanian GM; Zhong J; Healey LM; Corey A; Devalaraja M; Lo L; Ullrich S; Zimmerman J; Chen A; Lewis M; Meister G; Gillum K; Sanford D; Mott J; Bolmer SD
N Engl J Med; 2009 Jul; 361(2):135-44. PubMed ID: 19587338
[TBL] [Abstract][Full Text] [Related]
34. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000.
Cavallo JD; Ramisse F; Girardet M; Vaissaire J; Mock M; Hernandez E
Antimicrob Agents Chemother; 2002 Jul; 46(7):2307-9. PubMed ID: 12069996
[TBL] [Abstract][Full Text] [Related]
35. Newly developed colorimetric drug screening assay for Bacillus anthracis.
Barrow EW; Valderas MW; Bourne PC; Barrow WW
Int J Antimicrob Agents; 2006 Feb; 27(2):178-80. PubMed ID: 16423510
[No Abstract] [Full Text] [Related]
36.
Steenbergen J; Tanaka SK; Miller LL; Halasohoris SA; Hershfield JR
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223382
[TBL] [Abstract][Full Text] [Related]
37. Anthrax: an update.
Kamal SM; Rashid AK; Bakar MA; Ahad MA
Asian Pac J Trop Biomed; 2011 Dec; 1(6):496-501. PubMed ID: 23569822
[TBL] [Abstract][Full Text] [Related]
38. Anthrax: safe treatment for children.
Benavides S; Nahata MC
Ann Pharmacother; 2002 Feb; 36(2):334-7. PubMed ID: 11847958
[TBL] [Abstract][Full Text] [Related]
39. Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity.
Yamamoto BJ; Shadiack AM; Carpenter S; Sanford D; Henning LN; O'Connor E; Gonzales N; Mondick J; French J; Stark GV; Fisher AC; Casey LS; Serbina NV
Antimicrob Agents Chemother; 2016 Oct; 60(10):5787-95. PubMed ID: 27431222
[TBL] [Abstract][Full Text] [Related]
40. Modeling low-dose mortality and disease incubation period of inhalational anthrax in the rabbit.
Gutting BW; Marchette D; Sherwood R; Andrews GA; Director-Myska A; Channel SR; Wolfe D; Berger AE; Mackie RS; Watson BJ; Rukhin A
J Theor Biol; 2013 Jul; 329():20-31. PubMed ID: 23567649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
